Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Authors:

van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D.

Publication Type:

Journal Article

Publication Name:

BMC cancer

Citation:

van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer. 2016;16:598.


Link to publication ⟶

⟵ Back to Search Results